Regent China Post-Market Clinical Follow-up Study

Inclusion Criteria:

1. Patient is eligible to be implanted with Regent to replace a native or prostheticaortic valve per Regent's IFU.

2. Subject will be >18 years of age at time of being consented.

3. Subject, provides written informed consent prior to any clinicalinvestigation-specific procedure.

Exclusion Criteria:

1. Subject is unable to tolerate anticoagulation therapy.

2. Subject has active endocarditis.

3. Subject is currently participating in another clinical investigation which mayinterfere with the effectiveness of anticoagulation therapy.

4. Pregnant or nursing subjects and those who plan pregnancy during the clinicalinvestigation follow-up period. Women of child-bearing potential must have adocumented negative pregnancy test within one week prior to enrollment.

5. Subject has anomalous anatomy or medical, surgical, psychological or social historyor conditions that, in the investigator's opinion, could limit the subject's abilityto participate in the clinical investigation or to comply with follow-uprequirements of the clinical investigation results.

6. Subject is unable to read or write or has a mental illness or disability thatimpairs their ability to provide written informed consent.

7. Subject's life expectancy is less than 1 year in the opinion of the Investigator.